Antibe Therapeutics Inc (ATE) Analysts See $-0.01 EPS

November 20, 2017 - By Marguerite Chambers

 Antibe Therapeutics Inc (ATE) Analysts See $ 0.01 EPS

Investors wait Antibe Therapeutics Inc (CVE:ATE) to report on December, 5. its quarterly earnings Wall Street analysts expect $-0.01 EPS, $0.00 or 0.00 % from last year’s $-0.01 same quarter earnings. Antibe Therapeutics Inc’s Wall Street analysts see -50.00 % EPS growth, taking into account the $-0.02 EPS reproted in the previous quarter, It is down 0.00% since November 20, 2016 and is . It has underperformed by 16.70% the S&P500.

Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The company has market cap of $15.48 million. The Firm is focused on pain, inflammation and regenerative medicine. It currently has negative earnings. The Company’s divisions include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places.

More notable recent Antibe Therapeutics Inc (CVE:ATE) news were published by: Businesswire.com which released: “Antibe Therapeutics Announces Strategic Transactions” on October 06, 2015, also Businesswire.com with their article: “Antibe Therapeutics Announces Successful Phase 2 Trial of ATB-346 in …” published on August 08, 2016, Businesswire.com published: “Antibe Therapeutics Announces Enrollment of First Subjects in Phase 2B GI …” on September 08, 2017. More interesting news about Antibe Therapeutics Inc (CVE:ATE) were released by: Businesswire.com and their article: “Antibe Therapeutics Enters into Regional Licensing Deal” published on February 24, 2017 as well as Businesswire.com‘s news article titled: “Antibe Therapeutics Reports Q1 2018 Interim Financial and Operating Results” with publication date: August 29, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.